Arumakimig

阿鲁奇米单抗

Report date: 2026/04/21 20:00:18

Base Information

Drug NameArumakimig
Drug Alias NameMAS-825MAS825
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-1 beta inhibitorsInterleukin 18 inhibitors
TargetsInterleukin-1 betaInterleukin 18
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Autoimmune Lymphoproliferative SyndromeCoronary Disease +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAutoimmune Lymphoproliferative SyndromeCoronary DiseaseEnterocolitis +[4
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A